Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1645666/000156459021060020/kzr-8k_20211209.htm
August 2022
July 2022
June 2022
June 2022
May 2022
May 2022
May 2022
March 2022
January 2022
December 2021
Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1645666/000156459021060020/kzr-8k_20211209.htm
Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Kezar Life Sciences, Inc..
Kezar Life Sciences, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:
Financial Statements, Disclosures and Schedules
Inside this 8-K Corporate News
Ticker: KZREvents:
CIK: 1645666
Form Type: 8-K Corporate News
Accession Number: 0001564590-21-060020
Submitted to the SEC: Fri Dec 10 2021 4:10:28 PM EST
Accepted by the SEC: Fri Dec 10 2021
Period: Thursday, December 9, 2021
Industry: Pharmaceutical Preparations